Clinical Trials Logo

Neoplasm of Lung clinical trials

View clinical trials related to Neoplasm of Lung.

Filter by:

NCT ID: NCT03123783 Completed - Cancer Clinical Trials

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Start date: July 10, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.